DIASURV^® · PROGNOSIS PREDICTION

How could recurrence riskshape treatment and follow-up?

DiaSurv^®^* focuses on distinguishing higher-risk and lower-risk patients, with the goal of helping tailor treatment intensity and follow-up.

OPEN FOR RESEARCH COLLABORATIONResearch Use Only · Not for diagnostic procedures

Help match treatment intensity to each patient’s needs.

Recurrence risk and expected treatment benefit are central to avoiding overtreatment and undertreatment. These questions drive the development of DiaSurv^®^* and DiaThera^®^*.

Early-stage melanoma prognosis, read from the diagnostic slide.

0gene
panel.

The prognostic signal is read from the slide, not from a molecular test.

0sample
to ship.

The analysis runs on the slide already prepared at diagnosis, nothing leaves your lab.

0days
waiting.

The result comes with the pathology report, in the same workflow.

MELANOMA

Independent risk stratification

What could tissue analysis add to your assessment of melanoma recurrence risk?Overall survival, recurrence-free survival and distant metastasis-free survival beyond AJCC8 staging.

↗︎COLORECTAL

Recurrence risk

Explore recurrence risk in stage II T3/T4, MMR-proficient colorectal cancer.

↗︎

BREAST

Recurrence & survival

Characterization of tumor biology in early-stage HR+/HER2− breast cancer.

↗︎

CLINICAL PERSPECTIVE

From expertise
to implementation.

A testimonial on the realities of translating innovation into clinical practice.

CLINICAL PERSPECTIVE

From expertise to implementation.

A testimonial on the realities of translating innovation into clinical practice.

EVIDENCE

Evidence behind the risk.

DiaSurv^® is being studied through international, multi-center research programs with clinical and academic partners.

View all 19 publications ↗︎

La Presse Médicale · 2026

Artificial Intelligence applied to surgical pathology in the management of cutaneous melanoma

Surgical pathology remains the cornerstone for the diagnosis, staging and prognostic stratification of cutaneous melanoma. The emergence of digital pathology…

Validation of DiaSurv an AI-Based Algorithm for Stage II Colon Risk Stratification

Adjuvant chemotherapy decisions in stage II colon cancer (IIA T3N0; IIB T4aN0; IIC T4bN0) remain challenging, as conventional risk factors poorly predict…

Validation of DiaSurv, an AI-based algorithm for stage II colon cancer risk stratification

Adjuvant chemotherapy decisions in stage II colon cancer (IIA T3N0; IIB T4aN0; IIC T4bN0) remain challenging, as conventional risk factors poorly predict…

Discuss your prognosis project.

Start a research conversation ↗︎